R Squared Ltd Takes Position in Integer Holdings Corporation $ITGR

R Squared Ltd purchased a new stake in Integer Holdings Corporation (NYSE:ITGR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,960 shares of the medical equipment provider’s stock, valued at approximately $364,000.

Other large investors also recently made changes to their positions in the company. Intech Investment Management LLC lifted its stake in shares of Integer by 92.8% in the 1st quarter. Intech Investment Management LLC now owns 22,682 shares of the medical equipment provider’s stock valued at $2,677,000 after purchasing an additional 10,915 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Integer in the 1st quarter valued at $916,000. Russell Investments Group Ltd. lifted its stake in shares of Integer by 14.7% in the 1st quarter. Russell Investments Group Ltd. now owns 6,749 shares of the medical equipment provider’s stock valued at $796,000 after purchasing an additional 863 shares during the period. KLP Kapitalforvaltning AS lifted its stake in shares of Integer by 6.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 7,000 shares of the medical equipment provider’s stock valued at $861,000 after purchasing an additional 400 shares during the period. Finally, Aberdeen Group plc lifted its stake in shares of Integer by 38.5% in the 2nd quarter. Aberdeen Group plc now owns 319,229 shares of the medical equipment provider’s stock valued at $39,256,000 after purchasing an additional 88,784 shares during the period. Institutional investors and hedge funds own 99.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Wells Fargo & Company reissued an “equal weight” rating and issued a $80.00 price target (down previously from $132.00) on shares of Integer in a research note on Friday. Piper Sandler cut their price target on Integer from $155.00 to $82.00 and set an “overweight” rating on the stock in a research note on Friday. Wall Street Zen cut shares of Integer from a “buy” rating to a “hold” rating in a research report on Saturday. Argus cut shares of Integer from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Benchmark restated a “hold” rating on shares of Integer in a research report on Friday. Four research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Integer currently has an average rating of “Hold” and an average price target of $97.75.

Integer Price Performance

ITGR opened at $72.94 on Friday. The company has a quick ratio of 2.18, a current ratio of 3.71 and a debt-to-equity ratio of 0.70. Integer Holdings Corporation has a 12 month low of $66.50 and a 12 month high of $146.36. The company has a fifty day simple moving average of $103.61 and a 200 day simple moving average of $112.44. The stock has a market cap of $2.56 billion, a P/E ratio of 30.52, a P/E/G ratio of 0.58 and a beta of 0.97.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, October 23rd. The medical equipment provider reported $1.79 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.11. The business had revenue of $467.69 million during the quarter, compared to analysts’ expectations of $466.45 million. Integer had a net margin of 4.75% and a return on equity of 12.84%. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.43 EPS. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. On average, research analysts expect that Integer Holdings Corporation will post 6.01 EPS for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.